Trial Profile
Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.